The mTOR pathway is frequently dysregulated in cancer. Mutations, amplifications, or activation of upstream regulators such as the PI3K/AKT pathway can lead to hyperactivation of mTOR signaling. This dysregulation promotes uncontrolled cell growth and survival, contributing to the development and progression of cancer.
